Glucagon-like peptide-1 (GLP-1) is a powerful satiety hormone secreted by the intestines within minutes of eating, acting as a rapid messenger across multiple organ systems to regulate digestion and energy balance. In the pancreas, GLP-1 elegantly controls blood sugar by stimulating insulin release only when glucose is elevated—preventing hypoglycemia—while simultaneously suppressing glucagon to halt the liver's glucose output. Meanwhile, it slows gastric emptying in the stomach to blunt post-meal sugar spikes and prolong physical fullness, while concurrently signaling the brain's appetite centers (both directly and via the vagus nerve) to quickly reduce the desire to eat. Naturally designed as a sharp, meal-linked pulse rather than a continuous background signal, naturally produced GLP-1 has a brief half-life of under two minutes before it is rapidly deactivated by the DPP-4 enzyme, ensuring the body registers the meal and efficiently completes its metabolic cascade.

Glucose-dependent insulinotropic peptide (GIP) is secreted from K-cells in the upper small intestine within minutes of food reaching the duodenum. Like GLP-1, it is a potent stimulator of insulin secretion in a glucose-dependent manner — and for decades, GIP was considered the primary incretin hormone, with GLP-1 seen as a supporting player. More recent research has revised this understanding considerably.

GIP also acts on adipose tissue, promoting fat storage — an effect that in the context of chronic caloric excess has unfavorable metabolic consequences, which may explain why GIP receptor responsiveness is often reduced in people with obesity and type 2 diabetes. However, when GIP is activated in combination with GLP-1 — as happens naturally after a meal, and as has been exploited in newer dual-agonist pharmaceutical agents — it contributes meaningfully to appetite suppression, metabolic improvement, and weight loss.

Peptide YY (PYY) is co-secreted with GLP-1 from L-cells, primarily in the ileum and colon. While GLP-1 acts rapidly and is quickly cleared, PYY has a longer circulating half-life, providing a sustained satiety signal that persists for several hours after a meal. It acts on receptors in the hypothalamus to reduce appetite, and it slows the movement of food through the gut — the so-called “ileal brake” — giving the body more time to process and absorb nutrients.

PYY levels are notably lower in people with obesity compared to lean individuals, and they respond less robustly to meals. This blunted PYY response contributes to the reduced post-meal satiety that many people with weight challenges describe — the sense that fullness never quite arrives, or arrives too late and too briefly.

Oxyntomodulin is a further L-cell product that has both appetite-suppressing and energy expenditure-increasing effects — a combination that makes it particularly valuable in the satiety system. GLP-2, while not directly involved in appetite regulation, plays a critical role in maintaining the integrity of the intestinal lining, supporting the gut barrier that keeps inflammatory molecules from leaking into the bloodstream.

Both are released in concert with GLP-1 and PYY — part of the same integrated enteroendocrine response to a meal. This co-secretion is important: these hormones are not designed to work in isolation. They function as an ensemble, each contributing a distinct note to the satiety signal.